172 related articles for article (PubMed ID: 17901830)
21. Aromatase inhibitors: a time for reflection.
Birge SJ
Menopause; 2007; 14(6):971-2. PubMed ID: 17975522
[No Abstract] [Full Text] [Related]
22. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
Pritchard KI
Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
[No Abstract] [Full Text] [Related]
23. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
24. U.K. breast surgeons value the informational role of breast care nurses.
Pleat JM; Bailey JM; Dunkin CS
Breast J; 2004; 10(5):460-1. PubMed ID: 15327506
[No Abstract] [Full Text] [Related]
25. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
26. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy for breast disease: the nurse's role.
Warren B
Cancer Nurs; 1979 Feb; 2(1):32-7. PubMed ID: 253619
[No Abstract] [Full Text] [Related]
28. Advances in breast conservation therapy.
Newman LA; Kuerer HM
J Clin Oncol; 2005 Mar; 23(8):1685-97. PubMed ID: 15755977
[No Abstract] [Full Text] [Related]
29. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Seo JH; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
[TBL] [Abstract][Full Text] [Related]
30. Effectively nursing patients receiving aromatase inhibitor therapy.
Wengström Y
Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
[TBL] [Abstract][Full Text] [Related]
31. Primary breast cancer: risk factors, diagnosis and management.
Dean A
Nurs Stand; 2008 Jun 11-17; 22(40):47-55; quiz 58, 60. PubMed ID: 18610933
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
[TBL] [Abstract][Full Text] [Related]
33. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
34. Cardiotoxicities of breast cancer treatment.
Viale PH; Yamamoto DS
Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):19-24. PubMed ID: 19856594
[No Abstract] [Full Text] [Related]
35. [Is precautionary chemotherapy useful after mastectomy?].
Vitale V
Minerva Chir; 1973 Oct; 28(20):1367-9. PubMed ID: 4765906
[No Abstract] [Full Text] [Related]
36. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
[No Abstract] [Full Text] [Related]
37. Aromatase inhibitor-associated bone loss.
Bryce J; Bauer M; Hadji P
Oncol Nurs Forum; 2011 May; 38(3):273-6. PubMed ID: 21531678
[No Abstract] [Full Text] [Related]
38. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer.
Vestergaard P; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2008 May; 82(5):334-40. PubMed ID: 18463912
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
Morris PG; Bach PB
Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
[No Abstract] [Full Text] [Related]
40. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
